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ABSTRACT 
This study investigated the potential antinociceptive efficacy of a novel synthetic 
curcuminoid analogue, 2,6-bis-(4-hydroxy-3-methoxybenzylidene)cyclohexanone (BHMC), 
using chemical- and thermal-induced nociception test models in mice. BHMC (0.03, 0.1, 0.3 
and 1.0 mg/kg) administered via intraperitoneal route (i.p.) produced significant dose-related 
inhibition in the acetic acid-induced abdominal constriction test in mice with an ID50 of 0.15 
(0.13–0.18) mg/kg. It was also demonstrated that BHMC produced significant inhibition in 
both neurogenic (first phase) and inflammatory phases (second phase) of the formalin-
induced paw licking test with an ID50 of 0.35 (0.27–0.46) mg/kg and 0.07 (0.06–0.08) mg/kg, 
respectively. Similarly, BHMC also exerted significant increase in the response latency 
period in the hot-plate test. Moreover, the antinociceptive effect of the BHMC in the 
formalin-induced paw licking test and the hot-plate test was antagonized by pre-treatment 
with the non-selective opioid receptor antagonist, naloxone. Together, these results indicate 
that the compound acts both centrally and peripherally. In addition, administration of BHMC 
exhibited significant inhibition of the neurogenic nociception induced by intraplantar 
injections of glutamate and capsaicin with ID50 of 0.66 (0.41–1.07) mg/kg and 0.42 (0.38–
0.51) mg/kg, respectively. Finally, it was also shown that BHMC-induced antinociception 
was devoid of toxic effects and its antinociceptive effect was associated with neither muscle 
relaxant nor sedative action. In conclusion, BHMC at all doses investigated did not cause any 
toxic and sedative effects and produced pronounced central and peripheral antinociceptive 
activities. The central antinociceptive activity of BHMC was possibly mediated through 
activation of the opioid system as well as inhibition of the glutamatergic system and TRPV1 
receptors, while the peripheral antinociceptive activity was perhaps mediated through 
inhibition of various inflammatory mediators. 
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